Alnylam Pharmaceuticals Income from Continuous Operations 2010-2024 | ALNY
Alnylam Pharmaceuticals income from continuous operations for the twelve months ending June 30, 2024 was $-0.073B, a 93.14% decline year-over-year.
- Alnylam Pharmaceuticals annual income from continuous operations for 2023 was $-0.44B, a 61.08% decline from 2022.
- Alnylam Pharmaceuticals annual income from continuous operations for 2022 was $-1.131B, a 32.64% increase from 2021.
- Alnylam Pharmaceuticals annual income from continuous operations for 2021 was $-0.853B, a 0.64% decline from 2020.